GlobeNewswire: The Leona M. and Harry B. Helmsley Charitable Trust Contains the last 10 of 21 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:39:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/04/15/1804192/0/en/Helmsley-Charitable-Trust-Grants-4-3-Million-to-Develop-Tools-for-the-Clinical-Testing-of-Anti-fibrotic-Treatments-for-Crohn-s-Disease-Patients.html?f=22&fvtc=4&fvtv=19074Helmsley Charitable Trust Grants $4.3 Million to Develop Tools for the Clinical Testing of Anti-fibrotic Treatments for Crohn’s Disease Patients2019-04-15T16:32:47Z<![CDATA[Cleveland Clinic, Mayo Clinic, and Robarts Clinical Trials will collaborate to address a critical unmet treatment need for people with Crohn’s disease Cleveland Clinic, Mayo Clinic, and Robarts Clinical Trials will collaborate to address a critical unmet treatment need for people with Crohn’s disease]]>https://www.globenewswire.com/news-release/2018/01/16/1290143/0/en/Helmsley-Charitable-Trust-Announces-Funding-Opportunity-to-Advance-Disruptive-Technologies-for-Type-1-Diabetes.html?f=22&fvtc=4&fvtv=19074Helmsley Charitable Trust Announces Funding Opportunity to Advance Disruptive Technologies for Type 1 Diabetes2018-01-16T21:45:00Z<![CDATA[New York, NY, Jan. 16, 2018 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust’s Type 1 Diabetes (T1D) Program today announced a funding opportunity through the new Future Technologies Initiative. Helmsley’s Future Technologies Initiative aims to accelerate the development of novel, early-stage, disruptive technologies that have the potential to change the current state of T1D management and significantly improve glucose control while reducing the burden for people living with T1D.]]>https://www.globenewswire.com/news-release/2017/11/06/1175101/0/en/Helmsley-Charitable-Trust-Awards-52-Million-to-Support-the-Global-Platform-for-the-Prevention-of-Autoimmune-Diabetes.html?f=22&fvtc=4&fvtv=19074Helmsley Charitable Trust Awards $52 Million to Support the Global Platform for the Prevention of Autoimmune Diabetes2017-11-06T14:00:00Z<![CDATA[International Platform Will Enable Research Institutions to Conduct Newborn Genetic Screening and Carry out Primary Prevention Strategies for Type 1 Diabetes International Platform Will Enable Research Institutions to Conduct Newborn Genetic Screening and Carry out Primary Prevention Strategies for Type 1 Diabetes]]>https://www.globenewswire.com/news-release/2017/03/28/945876/10166351/en/Helmsley-Grants-5-Million-to-Study-Rise-of-Crohn-s-Disease-in-the-East.html?f=22&fvtc=4&fvtv=19074Helmsley Grants $5 Million to Study Rise of Crohn's Disease in the East2017-03-28T13:09:03Z<![CDATA[ENIGMA researchers in Hong Kong and Australia will investigate environmental triggers of inflammatory bowel diseases NEW YORK, N.Y., March 28, 2017 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust has provided a total of $5.2 million to the Australasian Gastro Intestinal Research Foundation (AGIRF) and the Chinese University of Hong Kong (CUHK) to study environmental factors that influence the development of inflammatory bowel diseases (IBD), which have been rising in Asia.]]>https://www.globenewswire.com/news-release/2017/03/16/940191/10166332/en/Helmsley-Charitable-Trust-and-Akston-Biosciences-Corporation-Announce-Partnership-to-Advance-Novel-Technology-to-Treat-Type-1-Diabetes.html?f=22&fvtc=4&fvtv=19074Helmsley Charitable Trust and Akston Biosciences Corporation Announce Partnership to Advance Novel Technology to Treat Type 1 Diabetes2017-03-16T13:33:54Z<![CDATA[New Therapy Will Target Cells Responsible for Autoimmune Disease NEW YORK, NY and BEVERLY, MA, March 16, 2017 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust and Akston Biosciences Corporation today announced a partnership to advance Akston's novel insulin engineering technology to prevent the clinical onset of type 1 diabetes. Akston's lead product candidate, AKS-107, is designed to be injected in at-risk, pre-diabetic individuals to disrupt problematic cells that may be responsible for type 1 diabetes, thereby reducing the chances that individuals develop diabetes.]]>https://www.globenewswire.com/news-release/2017/03/16/940192/10166332/en/Helmsley-Charitable-Trust-and-Akston-Biosciences-Corporation-Announce-Partnership-to-Advance-Novel-Technology-to-Treat-Type-1-Diabetes.html?f=22&fvtc=4&fvtv=19074Helmsley Charitable Trust and Akston Biosciences Corporation Announce Partnership to Advance Novel Technology to Treat Type 1 Diabetes2017-03-16T13:33:54Z<![CDATA[New Therapy Will Target Cells Responsible for Autoimmune Disease NEW YORK, NY and BEVERLY, MA, March 16, 2017 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust and Akston Biosciences Corporation today announced a partnership to advance Akston's novel insulin engineering technology to prevent the clinical onset of type 1 diabetes. Akston's lead product candidate, AKS-107, is designed to be injected in at-risk, pre-diabetic individuals to disrupt problematic cells that may be responsible for type 1 diabetes, thereby reducing the chances that individuals develop diabetes.]]>https://www.globenewswire.com/news-release/2017/03/14/936327/10166326/en/FasterCures-to-Further-Accelerate-Biomedical-Innovation-with-3-Million-Grant-from-Helmsley-Charitable-Trust.html?f=22&fvtc=4&fvtv=19074FasterCures to Further Accelerate Biomedical Innovation with $3 Million Grant from Helmsley Charitable Trust2017-03-14T13:36:53Z<![CDATA[Multi-Year Partnership Will Support Patient Engagement and Cross-Sector Collaboration Programs NEW YORK, March 14, 2017 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust has awarded ]]>https://www.globenewswire.com/news-release/2016/04/07/826837/10161658/en/Helmsley-Charitable-Trust-Awards-2-1-Million-to-Penn-Stanford-and-Seattle-Children-s-Research-Institute-to-Explore-Cell-Based-Therapies-for-Type-1-Diabetes.html?f=22&fvtc=4&fvtv=19074Helmsley Charitable Trust Awards $2.1 Million to Penn, Stanford and Seattle Children's Research Institute to Explore Cell-Based Therapies for Type 1 Diabetes2016-04-07T13:05:57Z<![CDATA[NEW YORK, April 7, 2016 (GLOBE NEWSWIRE) -- The Type 1 Diabetes (T1D) Program of The Leona M. and Harry B. Helmsley Charitable Trust has announced $2.1 million in grants to support research toward the creation of new T1D-specific cell therapies that could help delay or halt the progression of the disease. The new investment will support three complementary projects at the University of Pennsylvania, Stanford University and Seattle Children's Research Institute, which will collaborate with the Benaroya Research Institute.]]>https://www.globenewswire.com/news-release/2016/02/03/807483/10159775/en/Helmsley-Charitable-Trust-Awards-3-4-Million-to-DreaMed-Diabetes-for-Type-1-Diabetes-Decision-Support.html?f=22&fvtc=4&fvtv=19074Helmsley Charitable Trust Awards $3.4 Million to DreaMed Diabetes for Type 1 Diabetes Decision Support2016-02-03T21:22:04Z<![CDATA[NEW YORK, N.Y., Feb. 3, 2016 (GLOBE NEWSWIRE) -- The Type 1 Diabetes Program of The Leona M. and Harry B. Helmsley Charitable Trust today announced a $3.4 million grant for DreaMed Diabetes (DreaMed). The funding will support DreaMed's MD-Logic Pump Advisor, an algorithm that mimics expert clinicians' analysis of type 1 diabetes (T1D) data to make insulin dosing recommendations for patients. This type of decision support has the potential to ease the burden of the disease and improve glucose control, quality of life and health outcomes for people living with T1D.]]>https://www.globenewswire.com/news-release/2015/10/28/780832/10154318/en/Public-Mapping-and-Data-Tool-Creates-New-Way-to-Visualize-and-Analyze-Well-Being-and-Inequality-in-New-York-City.html?f=22&fvtc=4&fvtv=19074Public Mapping and Data Tool Creates New Way to Visualize and Analyze Well-Being and Inequality in New York City2015-10-28T12:14:28Z<![CDATA[DATA2GO.NYC by Measure of America offers free, easy access to federal, state, and local data; 350 indicators of New Yorkers' well-being in each of the city's 59 community districts NEW YORK, Oct. 28, 2015 (GLOBE NEWSWIRE) -- The nonprofit Measure of America today released ]]>